Symbols

ALZN

Alzamend Neuro·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ALZN

Alzamend Neuro, Inc.

An early clinical-stage biopharmaceutical company that developing novel products for the Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder

Industry

Pharmaceutical

Established Date

02/26/2016

Listing Date

06/15/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

04-30

Website

www.alzamend.com

Security Type

Common stock

Office address

3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA 30326

Business

Introduction

Alzamend Neuro, Inc., was incorporated in Delaware on February 26, 2016. The company is a clinical-stage biopharmaceutical company focused on developing new products for the treatment of Alzheimer's disease, bipolar disorder, major depression and post-traumatic stress disorder. The company has launched two product candidates with the goal of bringing treatments not only for Alzheimer's disease, but also bipolar disorder, major depression and post-traumatic stress disorder. The company has developed a new way to fight Alzheimer's through immunotherapy.

Company Financials

EPS

ALZN has released its 2026 Q2 earnings. EPS was reported at -0.3, versus the expected -1.96, beating expectations. The chart below visualizes how ALZN has performed over recent quarters, highlighting trends in earnings surprises.